3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
53
Ovarian Neoplasms
4
Prostatic Neoplasms
3
Neoplasms
3
Inflammatory Breast Neoplasms
3
HER2-positive Breast Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Solid Tumor
2
Rectal Neoplasms
2
Neoplasm Metastasis
2
Colonic Neoplasms
2
Urinary Bladder Neoplasms
1
Solid Cancers
1
Patient Preference
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Multiple Endocrine Neoplasia
1
Malignant Solid Neoplasm
1
Lung Neoplasms
1
Locally Advanced Breast Cancer
1
Her2-Positive Breast Cancer
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-Positive Early Breast Cancer
1
HER2 Positive Breast Cancer
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Interventions
Gemcitabine
31
Cisplatin
21
pembrolizumab
8
Fluorouracil
6
Oxaliplatin
5
Capecitabine
5
130-nm albumin-bound paclitaxel
5
durvalumab
4
Taxes
4
Albumin-Bound Paclitaxel
4
pemigatinib
3
infigratinib
3
atezolizumab
3
Specimen Handling
3
Radiosurgery
3
Platinum
3
Magnetic Resonance Spectroscopy
3
Leucovorin
3
Carboplatin
3
Biopsy
3
1,2-diaminocyclohexaneplatinum II citrate
3
tremelimumab
2
trametinib
2
olaparib
2
ivosidenib
2
derazantinib
2
cobimetinib
2
Trastuzumab
2
Radiotherapy
2
Panitumumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Cholangiocarcinoma
×
pertuzumab
×
Clear all
No trials found.